Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis

Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis

At our center, relapsed mantle cell lymphoma (MCL) can be treated with maintenance therapy composed of consecutive low-dose lenalidomide and short-term, high-dose dexamethasone (LD regimen), which achieves good responses (longer overall survival and progression-free survival) and low toxicity. Cereb...

Full description

Bibliographic Details
Main Authors: Jiexian Ma, Kefei Wu, Weiya Bai, Xiaoxian Cui, Yan Chen, Youhua Xie, Yanhui Xie
Format: Article
Language:English
Published: Elsevier 2017-06-01
Series:EBioMedicine
Subjects:
Lenalidomide
Dexamethasone
Cereblon
MCL
IL-6/STAT3
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396417302128

Internet

http://www.sciencedirect.com/science/article/pii/S2352396417302128

Similar Items